BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18297152)

  • 1. From insulin to incretins: a report from the 67th scientific sessions of the American Diabetes Association.
    Rabasseda X
    Timely Top Med Cardiovasc Dis; 2007 Aug; 11():E21. PubMed ID: 18297152
    [No Abstract]   [Full Text] [Related]  

  • 2. Insight into antidiabetic therapies: a report from the 43rd annual meeting of the European Association for the Study of Diabetes.
    Rabasseda X
    Timely Top Med Cardiovasc Dis; 2007 Oct; 11():E28. PubMed ID: 18297140
    [No Abstract]   [Full Text] [Related]  

  • 3. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
    Hermansen K; Mortensen LS
    Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Diabetes Association - 67th Scientific Sessions: pros and cons of GLP-1 agonists and DPP-IV inhibitors.
    Toft AD
    IDrugs; 2007 Sep; 10(9):606-9. PubMed ID: 17786839
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
    Munir KM; Davis SN
    Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of type 2 diabetes.
    Hermans MP; Buysschaert M
    Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
    [No Abstract]   [Full Text] [Related]  

  • 7. A report from the 47th European Association for the Study of Diabetes annual meeting (September 12-16, 2011 - Lisbon, Portugal).
    Rabasseda X
    Drugs Today (Barc); 2011 Dec; 47(12):923-34. PubMed ID: 22348917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
    Brown A; Desai M; Taneja D; Tannock LR
    Postgrad Med; 2010 Jan; 122(1):163-71. PubMed ID: 20107300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New medications for patients with type 2 diabetes].
    Meillet L
    Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Programs for continuing medical education: a session; 7. Recent trends in treatment of diabetes mellitus].
    Namba M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):657-64. PubMed ID: 24796133
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB; Holman R; Drucker DJ
    N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
    [No Abstract]   [Full Text] [Related]  

  • 12. Seeking sweet relief for diabetes.
    Dove A
    Nat Biotechnol; 2002 Oct; 20(10):977-81. PubMed ID: 12355109
    [No Abstract]   [Full Text] [Related]  

  • 13. Complications of diabetes therapy.
    Corathers SD; Peavie S; Salehi M
    Endocrinol Metab Clin North Am; 2013 Dec; 42(4):947-70. PubMed ID: 24286957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
    Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes: the many facets of care.
    Hall MA
    Home Healthc Nurse; 2008 Jun; 26(6):346-53; quiz 354-5. PubMed ID: 18562819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 19. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
    DeGeeter M; Williamson B
    J Pharm Pract; 2016 Apr; 29(2):144-59. PubMed ID: 25312263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin physiology and its role in type 2 diabetes mellitus.
    Svec F
    J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.